<p>Pharmacological distribution diagram for natural Akt inhibitors obtained using the DF<sub>1</sub> (the black colour represents Akt inhibitors and the white colour, the compounds without Akt inhibition activity).</p
<p>DMH1 activated Akt and increased glucose metabolism; but compound C inhibited DMH1 –induced Akt a...
<p>Schematic illustration of different inhibition mechanisms and the associated DSF signatures: A) G...
Exposure of 1,000 simulated patients are represented as box plots in each lesion to visualize the di...
<p>Pharmacological distribution diagram for Akt inhibitors obtained using the DF<sub>2</sub> (the <i...
<p>Pharmacological distribution diagram for natural β-catenin inhibitors obtained using the DF<sub>3...
<p>Pharmacological distribution diagram for β-catenin inhibitors obtained using the DF<sub>4</sub> (...
<p>Upon activation by receptor tyrosine kinase, PI3K lipid kinases are recruited to the plasma membr...
<p>The inhibitor targets are indicated in red. The kinome diagram is adapted, with permission, from ...
The upset plot shows the detailed number of therapeutic peptides in each group. In the upset plot, t...
<p>The data points in square and circle represent training and test set compounds respectively.</p
<p>Schematic diagram of avibactam inhibition and deacylation pathways of KPC-2.</p
<p>Potency distribution profiles of 88 and 650 anticancer drugs and natural products.</p
<p>Schematic figure of the canonical versus non-canonical NF-κB signaling pathways, and downstream t...
<p>The schematic diagram of tissue distribution of Compound 1 in Wistar rats after 180/kg of orally ...
<p>Distribution of five molecular descriptors of natural products and approved drugs.</p
<p>DMH1 activated Akt and increased glucose metabolism; but compound C inhibited DMH1 –induced Akt a...
<p>Schematic illustration of different inhibition mechanisms and the associated DSF signatures: A) G...
Exposure of 1,000 simulated patients are represented as box plots in each lesion to visualize the di...
<p>Pharmacological distribution diagram for Akt inhibitors obtained using the DF<sub>2</sub> (the <i...
<p>Pharmacological distribution diagram for natural β-catenin inhibitors obtained using the DF<sub>3...
<p>Pharmacological distribution diagram for β-catenin inhibitors obtained using the DF<sub>4</sub> (...
<p>Upon activation by receptor tyrosine kinase, PI3K lipid kinases are recruited to the plasma membr...
<p>The inhibitor targets are indicated in red. The kinome diagram is adapted, with permission, from ...
The upset plot shows the detailed number of therapeutic peptides in each group. In the upset plot, t...
<p>The data points in square and circle represent training and test set compounds respectively.</p
<p>Schematic diagram of avibactam inhibition and deacylation pathways of KPC-2.</p
<p>Potency distribution profiles of 88 and 650 anticancer drugs and natural products.</p
<p>Schematic figure of the canonical versus non-canonical NF-κB signaling pathways, and downstream t...
<p>The schematic diagram of tissue distribution of Compound 1 in Wistar rats after 180/kg of orally ...
<p>Distribution of five molecular descriptors of natural products and approved drugs.</p
<p>DMH1 activated Akt and increased glucose metabolism; but compound C inhibited DMH1 –induced Akt a...
<p>Schematic illustration of different inhibition mechanisms and the associated DSF signatures: A) G...
Exposure of 1,000 simulated patients are represented as box plots in each lesion to visualize the di...